Company Analysis
Sign in

NervGen Pharma Corp. (NGEN)

Nasdaq: NGEN · Pharmaceutical Preparations · Vancouver, BC · filing with the SEC since 2018
Full chart Alerts Compare
Grade5.6
◀ Past 6.4● Present 4.0▶ Future 6.6
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-C$44.1M-81.9%
Earnings per shareC$-0.61-69.4%
Operating cash flow-C$19.5M-15.8%
CashC$22.1M+27.8%
Debtn/a
Shareholders’ equityC$3.5M+34.9%
Shares, diluted72.3M+7.4%
Return on equity-1268.9%
The recordfrom its filings
Filings in 202630
Newest filingOct 16 · 6-K/A
Annual reportMar 31, 2026
Quarterly reportn/a
Next report due40-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents grantedn/a
Filer category<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
2425
As filed, in CAD. Nothing here is a forecast.

News

Jul 2, 2026 · SEC EDGAR · Form SUPPL
Form SUPPL
Open the filing on sec.gov
May 26, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton NGEN · research, not advice